TREA

Descarbonylethoxyloratadine containing pharmaceutical composition

Follow

Information

  • Patent Application
  • 20070224266
  • Publication Number
    20070224266
  • Date Filed
    December 21, 2006
    17 years ago
  • Date Published
    September 27, 2007
    17 years ago
Information
Abstract
A pharmaceutical composition wherein the pharmaceutically active ingredient (i.e. drug component) comprises Descarbonylethoxyloratadine and which further comprises an acidic element and a pharmaceutically acceptable stabilizer element.
Description
Claims
  • 1. A pharmaceutical composition for oral administration comprising a pharmaceutically active component and a pharmaceutically acceptable carrier component, wherein said pharmaceutically active component comprises a DCL element, wherein said pharmaceutically acceptable carrier component comprises an acidic element, and wherein said composition further comprises a DCL-protective amount of a pharmaceutically acceptable stabilizer element selected from the group consisting of magnesium oxide, calcium oxide, aluminum oxide and mixtures thereof.
  • 2. A pharmaceutical composition as defined in claim 1 wherein said composition comprises up 10% by weight of said composition of said stabilizer element.
  • 3. A pharmaceutical composition as defined in claim 1 wherein said stabilizer element comprises magnesium oxide.
  • 4. A pharmaceutical composition as defined in claim 1 wherein said stabilizer element consists of magnesium oxide.
  • 5. A pharmaceutical composition as defined in claim 2 wherein said stabilizer element comprises from 1% to 10% by weight of said composition and wherein said stabilizer element comprises magnesium oxide.
  • 6. A pharmaceutical composition as defined in claim 2 wherein said stabilizer element comprises from 1% to 10% by weight of said composition and wherein said stabilizer element consists of magnesium oxide.
  • 7. A pharmaceutical composition as defined in any one of claims 1 to 6 wherein said acidic element comprises an acidic excipient element.
  • 8. A pharmaceutical composition as defined in claim 7 wherein said acidic excipient element is selected from the group consisting of lactose, microcrystalline cellulose and mixtures thereof.
  • 9. A pharmaceutical composition as defined in any one of claims 1 to 8 wherein said composition is in the form of a tablet.
  • 10. A pharmaceutical composition as defined in any of claims 1 to 9 wherein said stabilizer element comprises from 1% to 2.65% by weight of said composition.
Priority Claims (1)
Number Date Country Kind
2,541,045 Mar 2006 CA national